Marco Canfora

Marco Canfora

Auto-generated profile, based on publicly available information

Marco Canfora

Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2016 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
FMFrancesco Marchesi
Francesco Marchesi
ATA Tendas
A Tendas
DGDiana Giannarelli
Diana Giannarelli
CVC Viggiani
C Viggiani
SGS Gumenyuk
S Gumenyuk
AMAndrea Mengarelli
Andrea Mengarelli

1 January 2015 in World Journal of Transplantation
Verified
Journal Article
Open access
FMFrancesco Marchesi
Francesco Marchesi
FPFulvia Pimpinelli
Fulvia Pimpinelli
SGSvitlana Gumenyuk
Svitlana Gumenyuk
DRDaniela Renzi
Daniela Renzi
FPFrancesca Palombi
Francesca Palombi
AMAndrea Mengarelli
Andrea Mengarelli
To determine the incidence of and the risk factors for cytomegalovirus (CMV) symptomatic infection and end-organ disease after autologous stem cell transplantation (ASCT). A total of 327 consecutive non CD34(+) selected autografts performed from the Hematology and Stem Cell Transplantation Unit of Regina Elena National Cancer Institute of Rome (Italy) in the period comprised between January 2003 to January 2015, were reviewed. Over the 327 autografts, 201 were performed in patients with multiple myeloma, whereas the remaining 126 in patients affected by non-Hodgkin's lymphoma and Hodgkin's lymphoma. The patients who underwent an ASCT for an acute leukemia (n = 20) in the same period were excluded from this analysis. CMV DNA load in the blood has been determined by polymerase-chain reaction in the case of a clinical suspicion of reactivation, therefore, no routine monitoring strategy was adopted. In the presence of signs and symptoms of CMV reactivation an antiviral treatment was performed. Overall, 36 patients (11%) required a specific antiviral treatment for a symptomatic CMV reactivation (n = 32) or an end-organ disease (n = 4). We observed 20 and 16 cases of CMV reactivation among lymphoma (16%) and myeloma patients (8%), respectively. Among cases of end-organ disease, 3 were diagnosed as interstitial pneumonia and one remaining case as hemorrhagic enteritis. All cases of CMV reactivation were observed in IgG seropositive patients, with no documented cases of primary CMV infection. All patients were treated with a specific antiviral therapy, with a global rate of hospitalization of 55%; four patients received intravenous immunoglobulins. Transplant-related mortality was significantly higher in patients who experienced a CMV reactivation (8.4% ± 4.7% vs 1.7% ± 0.8%; P = 0.047). In univariate analysis, a pre-transplant HBcIgG seropositivity, a diagnosis of T-cell non-Hodgkin's lymphoma and higher median age at transplant were significantly associated with the risk of developing a clinically relevant CMV infection requiring specific antiviral therapy (P < 0.001, P = 0.042 and P = 0.004, respectively). In multivariate analysis, only a pre-transplant HBcIgG seropositivity (OR = 8.928, 95%CI: 1.991-33.321; P = 0.023) and a diagnosis of T-cell non-Hodgkin's lymphoma (OR = 4.739, 95%CI: 1.511-11.112; P = 0.042) proved to be independent predictors of a post-transplant clinically relevant CMV reactivation. A symptomatic CMV infection can occur in about 11% of adult patients with lymphoma or myeloma undergoing ASCT. A pre-transplant HBcIgG seropositivity and a diagnosis of T-cell non-Hodgkin's lymphoma should be considered as independent predictor factors of CMV reactivation.

1 February 2016 in Journal of Infection
Verified
Journal Article
Closed access
AMAndrea Mengarelli
Andrea Mengarelli
OAO. Annibali
O. Annibali
FPF. Pimpinelli
F. Pimpinelli
ERElisabetta Riva
Elisabetta Riva
SGS. Gumenyuk
S. Gumenyuk
FMFrancesco Marchesi
Francesco Marchesi

10 September 2016 in Chemotherapy
Verified
Journal Article
Closed access
DRDaniela Renzi
Daniela Renzi
FMFrancesco Marchesi
Francesco Marchesi
GAGottardo De Angelis
Gottardo De Angelis
LELoredana Elia
Loredana Elia
ESEmanuela Salvatorelli
Emanuela Salvatorelli
FNFor The Rome Transplant Network
For The Rome Transplant Network
We describe the case of a patient with a Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with dasatinib plus steroids as the first-line therapy who achieved a molecular complete remission and then underwent a matched, unrelated donor allogeneic transplant. Five months after the transplant, he experienced a disease relapse with an T315I mutation, which was resistant to salvage chemotherapy. Once the details of the T315I mutation were acquired, we initiated ponatinib treatment at a standard dosage and observed a rapid decrease of minimal residual disease (MRD) at molecular assessment. The bone marrow evaluation after 2, 3, 6, 10 and 13 months was negative for MRD. After starting ponatinib, the patient experienced a skin graft-versus-host disease (GVHD), whereas no occurrence of GVHD was observed after transplant, suggesting that the efficacy of ponatinib could be related not only to the direct antileukemic effect, but also to its ability to promote an indirect graft-versus-leukemia effect. Ponatinib was well tolerated but a thyroid dysfunction mimicking a cardiovascular toxicity was observed and solved with hormonal substitutive treatment.

17 June 2015 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
FMFrancesco Marchesi
Francesco Marchesi
SMSerena Masi
Serena Masi
VSValentina Summa
Valentina Summa
SGSvitlana Gumenyuk
Svitlana Gumenyuk
RMRoberta Merola
Roberta Merola
ICIole Cordone
Iole Cordone

18 July 2015 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
FMFrancesco Marchesi
Francesco Marchesi
MVMichele Vacca
Michele Vacca
SGSvitlana Gumenyuk
Svitlana Gumenyuk
APAnnino Pandolfi
Annino Pandolfi
DRDaniela Renzi
Daniela Renzi
AMAndrea Mengarelli
Andrea Mengarelli